MedImmune Delays Numax BLA Pending Additional RSV Trial Data
This article was originally published in The Pink Sheet Daily
Executive Summary
Company hopes data from a second Phase III trial, due at summer’s end, will make the application more attractive to FDA.
You may also be interested in...
MedImmune Files BLA For Pediatric RSV Candidate
PDUFA date for Numax (motavizumab) would be Nov. 30 under standard review.
MedImmune Files BLA For Pediatric RSV Candidate
PDUFA date for Numax (motavizumab) would be Nov. 30 under standard review.
MedImmune Inks Third Reverse Genetics Licensing Deal For Influenza Vaccines
Firm also reports positive data from second Phase III study of Synagis follow-on Numax.